Reclaiming Asia’s Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Established in 1960, CHA Health Systems (CHS) opened its first women’s medical center in Seoul, South Korea. CHS has received worldwide recognition and accolades for its excellence in clinical research and accomplishments in the fields of obstetrics and gynecology. It owns and operates, among others: Hollywood Presbyterian Medical Center, one of the largest privately-owned hospital in Los Angeles and 8 general acute-care hospital facilities throughout Korea. CHS continued its international expansion and formed CHAUM, a premier anti-aging center and 5 fertility treatment and research centers in the U.S. and Korea. The Company’s activities also include various medical and biotech ventures, including a healthcare investment firm, CHA Bio & Diostech, one of the largest biotechs listed in KOSDAQ.
CHS also introduces a premier anti-aging center, CHAUM, offering various treatments including western medicine, alternative medicine, stem-cell therapies, exercise prescription, and food therapies, targeting issues related to optimum health and wellness. It also operates a global CHAUM clinical trial center, the world’s only one-stop clinical trial center for regenerative medicine. In this center, GMP facility, surgery room, recovery room, treatment room, and in-hospitalization facility are centrally located for convenience and quality care. Its customized clinical trial services and state-of-the art facilities for the development of regenerative medicine are a major supplier to many biotech companies worldwide, which offers opportunities for small and large companies to carry out proof of concept studies and early phase clinical trials at substantial savings in time and money.
With the ultimate vision of becoming a global leader in the next generation of healthcare services, CHS continues to stay at the forefront of medical services by building its global network of hospitals/clinics and research institutes for the advancement of bio-medicine and bio-ventures.
Contact Details
Dong-kun Lee, Corporate Planning
335 Pangyo-Ro, Bundang-Gu, Seongnam City, Kyunggi-Do, Republic of Korea
Tel. (+82)31-881-7370 Cell (+82)10-9261-6160 Fax. (+82)31-881-7379
E-mail. ddkk.lee@chamc.co.kr
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
See our Cookie Privacy Policy Here
